Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Kansas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Kansas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Kansas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Shaker Dakhil (NPI 1417918079)

Field	Value
Entity Type	Individual
Organization	Shaker Dakhil
Address	818 N Emporia St Ste 403
City	Wichita
State	KS
ZIP	67214
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	March 31, 2006

Payer Source	Total Paid
Medicare	$4.4M
Medicaid	$0

Key Findings

This provider’s billed activity is effectively single‑payer: lifetime Medicare revenue is $4.4M and there is no Medicaid billing on file. The lack of any Medicaid claims suggests the practice derives virtually all reported public-payer reimbursement from Medicare beneficiaries, which implies a predominantly Medicare patient panel and exposure concentrated in that single federal payer.

Revenue is highly concentrated in a few oncology drug codes: the precomputed top three Medicare codes account for 48.2% of this provider’s Medicare revenue, driven by J9271 (27.6%), J9299 (12.0%), and J0897 (8.6%). Those codes point to a heavy reliance on high-volume oncology injectables as the primary revenue drivers.

The code mix indicates an infusion‑centric hematology/oncology practice that administers checkpoint inhibitors and supportive agents: high-revenue codes include J9271 and J9299 (immuno‑oncology agents), J0897 (bone‑targeting agent), J9145/J9144 (daratumumab formulations), and the chemotherapy administration code 96413. The presence of PET/CT imaging (78815) and IV supportive drugs (e.g., J1568, J1627) further supports a workflow built around recurring infusion visits and integrated imaging for staging or treatment monitoring.

Competitive standing is mixed by drug: the provider ranks #294 of 10057 for J0897 at the 97th percentile and the practice’s 96413 chemotherapy administration ranks #182 of 7514 at the 98th percentile, both labeled as “notably above typical national volume,” indicating above‑typical activity for bone‑modifying therapy and chemo administration. By contrast, J9271 ranks #187 of 1841 (90th percentile) and is characterized as “typical, unremarkable volume,” so the practice has strong relative presence for some supportive/administration codes while remaining a typical national participant for certain checkpoint inhibitors.

There are notable relative shortfalls for some monoclonal antibody therapies: daratumumab lines show modest standing (J9145 rank #10 of 14, 31st percentile; J9144 rank #477 of 615, 22nd percentile) and trastuzumab excluding biosimilars (J9355) ranks #7 of 8 (14th percentile). These lower percentiles suggest the practice does not compete at high volume nationally for certain specialty myeloma and HER2‑targeted infusion therapies despite strong activity in other oncology injectables.

Imaging and supportive care are meaningful ancillary revenue sources: 78815 (PET/CT fusion) generated $241.6K (5.8% of Medicare revenue) and ranks #896 of 6566 (86th percentile), while A9552 contributed $25.6K and ranks #257 of 2411 (89th percentile). These placements indicate routine use of advanced imaging to guide oncology care and a nontrivial role for imaging in the practice’s service mix.

Several administration/support codes appear as high relative outliers for volume, reinforcing an infusion practice profile: J0185 (aprepitant) ranks #39 of 819 at the 95th percentile and J0185 is listed as “notably above typical national volume,” while J1627 (granisetron extended‑release) and multiple growth‑factor/biosimilar codes (Q5107, Q5115, Q5108) show regular billing. This pattern reflects systematic, repeated supportive‑care regimens alongside the major oncology drug administrations.

The provider has long tenure in the NPI file, enumerated 2006-03-31 (~20 years ago), which supports interpretation of stable, established oncology practice operations and a sustained Medicare billing footprint over time.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

101 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	26,600	$40	$1.1M
J9299	Injection, nivolumab, 1 mg	21,520	$20	$495K
J0897	Injection, denosumab, 1 mg	19,860	$20	$357.5K
J1930	Injection, lanreotide, 1 mg	7,920	$40	$348.5K
J9145	Injection, daratumumab, 10 mg	6,580	$50	$309.3K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	230	$1,070	$241.6K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	5,220	$40	$203.6K
J9173	Injection, durvalumab, 10 mg	2,260	$60	$140.1K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	3,810	$30	$125.6K
Q5107	Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg	4,750	$20	$109.3K

Showing 1–10 of 101

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 101 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Kansas Distribution

Shaker Dakhil — 2 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Kansas

Full comparison — all codes billed, vs. state median

101 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	13	20	28,900	$40	$1.1M
J9299	10	10	24,550	$20	$637.2K
J1930	5	10	9,180	$40	$402.7K
J9145	6	10	6,660	$50	$394.7K
J9144	6	10	6,300	$40	$257.2K
J9173	6	10	3,480	$60	$230.3K
J1568	6	10	3,690	$30	$129K
Q5107	3	10	4,440	$20	$106.5K
Q5115	10	10	2,340	$30	$92.9K
J0897	4	180	2,160	$20	$81.5K

Showing 1–10 of 101

Related Providers

Other providers that share a Tax Identification Number (TIN) with Shaker Dakhil, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
David Dyer	KS	Ophthalmology Physician	$7.5M	$0
Bassam Mattar	KS	Hematology & Oncology Physician	$7.2M	$0
Dennis Moore	KS	Hematology & Oncology Physician	$6.7M	$0
Pavan Reddy	KS	Hematology & Oncology Physician	$6.7M	$0
Jeremy Deutsch	KS	Hematology & Oncology Physician	$5.7M	$0
Thomas Finley	OK	Ophthalmology Physician	$4.8M	$0
Daniel Feiler	KS	Ophthalmology Physician	$4.8M	$0
Travis Koeneke	KS	Hematology & Oncology Physician	$4.4M	$0
Christopher Dakhil	KS	Hematology & Oncology Physician	$4.4M	$0
Stephen Wiles	MO	Ophthalmology Physician	$4.4M	$0

Nearby Providers

Other providers in the same ZIP code as Shaker Dakhil, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Craig Resources LLC	KS	Home Health Agency	$0	$97.3M
Paradigm Services Inc	KS	Intellectual and/or Developmental Disabilities Residential Treatment Facility	$0	$42.4M
Wesley Medical Center LLC	KS	General Acute Care Hospital	$0	$30.2M
Gracemed Health Clinic Inc	KS	Federally Qualified Health Center (FQHC)	$0	$18.3M
Healthcore Clinic Inc	KS	Federally Qualified Health Center (FQHC)	$0	$15.3M
Diversified Family Services LLC	KS	Home Health Agency	$0	$13.9M
Alpha Service	KS	Developmentally Disabled Services Day Training Agency	$0	$12.1M
Carepoint Emergency Medicine Kansas LLC	KS	Emergency Medicine Physician	$0	$11.8M
Hunter Health Clinic Inc	KS	Federally Qualified Health Center (FQHC)	$0	$10.4M
Ascension Via Christi Hospitals Wichita Inc.	KS	General Acute Care Hospital	$0	$8.9M

Shaker Dakhil — Billing Profile & Reimbursement Data

Sign up for Shaker Dakhil — Billing Profile & Reimbursement Data policy alerts

Shaker Dakhil — Billing Profile & Reimbursement Data

Sign up for Shaker Dakhil — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References